Scholarlink

<p>This retrospective study evaluated the efficacy and safety of integrating blinatumomab and CD19 CAR T-cell therapy into frontline treatment for newly diagnosed adult Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. All patients received Hyper-CVAD-based consolidation with integrated immunotherapy. Forty patients were classified according to frontline immunotherapy strategy: single-modality therapy (BiTE/CART group, n = 22) or combined use of both modalities (BiTE + CART group, n = 18).&#xa0;After a median follow-up of 23.8&#xa0;months, the BiTE + CART group demonstrated significantly improved overall survival and relapse-free survival compared with the BiTE/CART group (2-year overall survival: 100% vs. 58.4%; 2-year relapse-free survival: 94.4% vs. 53.1%). A higher cumulative exposure to immunotherapy (≥ 4 cycles) was associated with improved outcomes. Notably, survival in non-transplanted patients was comparable to those undergoing allogeneic transplantation in first remission. These findings support the integration of blinatumomab and CD19 CAR T-cell therapy as a promising strategy to improve disease control in Ph⁻ B-cell precursor acute lymphoblastic leukemia, pending validation in prospective studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Combined blinatumomab and CD19 CAR T-cell therapy for newly diagnosed adult Ph⁻ BCP-ALL: A retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Boxuan Jiang,
  • Yiyan Zhu,
  • Yucheng Jiang,
  • Jiayi Huang,
  • Yizi Liu,
  • Meng Tang,
  • Jing Lu,
  • Suning Chen

摘要

This retrospective study evaluated the efficacy and safety of integrating blinatumomab and CD19 CAR T-cell therapy into frontline treatment for newly diagnosed adult Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. All patients received Hyper-CVAD-based consolidation with integrated immunotherapy. Forty patients were classified according to frontline immunotherapy strategy: single-modality therapy (BiTE/CART group, n = 22) or combined use of both modalities (BiTE + CART group, n = 18). After a median follow-up of 23.8 months, the BiTE + CART group demonstrated significantly improved overall survival and relapse-free survival compared with the BiTE/CART group (2-year overall survival: 100% vs. 58.4%; 2-year relapse-free survival: 94.4% vs. 53.1%). A higher cumulative exposure to immunotherapy (≥ 4 cycles) was associated with improved outcomes. Notably, survival in non-transplanted patients was comparable to those undergoing allogeneic transplantation in first remission. These findings support the integration of blinatumomab and CD19 CAR T-cell therapy as a promising strategy to improve disease control in Ph⁻ B-cell precursor acute lymphoblastic leukemia, pending validation in prospective studies.